Project Grant R03HL174881
Award Date
8/26/24
Completion Date
7/31/26
Dollars Obligated
$119K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $711,039 to the Research Institute at Nationwide Children's Hospital to conduct research on the role of cardiac m6A methyltransferases in the pathogenesis of fetal dilated cardiomyopathy (DCM). The key objectives are to determine the functions of the m6A methyltransferases METTL3 and METTL14 in embryonic mouse myocardium and whether their...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $751,747 to the University of North Carolina at Chapel Hill to conduct research on the role of the protein arginine methyltransferase CARM1 in regulating cardiomyocyte (CM) maturation. The research aims to define key factors and signaling pathways that control CM structural, functional, and electrophysiological maturation at both...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under CFDA Program 93.837 Cardiovascular Diseases Research, provides $561,392 to the University of Alabama at Birmingham (UAB) to investigate the role of RNA methylation in the progression of cardiac fibrosis and heart failure. The research aims to elucidate how the enzyme METTL3 regulates the stability of the RAPGEF5 mRNA, which in turn impacts B-catenin-mediated fibrotic signaling. The project will...
This federal Project Grant award of $2,249,307, provided by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research), aims to study the premature maturation arrest of pluripotent-derived cardiomyocytes (PSC-CMs) and develop strategies to overcome this issue. The project will leverage a high-resolution single cell transcriptome map of endogenous cardiomyocyte maturation to identify a critical gene regulatory network underlying the maturation failure in PSC-CMs....
This $506,984 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to investigate the role of the LRP1 gene in the development of congenital heart disease (CHD). The primary objectives are to: Examine the deployment and migration of cardiac neural crest cells (CNCCs) and their dependence on LRP1 using in vitro and in vivo cell lineage fate mapping analysis. Investigate the cellular and molecular...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $243,000 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Cincinnati's Sponsored Research Services Division. The grant will fund a 2-year project to engineer advanced RNA biodevices that leverage CRISPR and ADAR gene-editing technologies. The goal is to improve the efficiency and specificity of converting resident cardiac fibroblasts into functional cardiomyocytes, in order to boost...
This $701,842 Project Grant, awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), will support research at the University of South Florida to investigate the role of the CDK13 gene in the development of congenital heart defects. The project aims to utilize mouse models and human induced pluripotent stem cell-derived cardiomyocytes to better understand how mutations in CDK13 disrupt RNA processing and lead to cardiac...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $540,856 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Regents of the University of California, San Francisco (UCSF) on Dec 15, 2024. The goal of this 4-year project is to identify transcriptional regulators that control endocardial-specific gene expression and valve development, as well as understand the regulation and function of the SLC16A2 gene during heart injury and regeneration. The...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $1,137,498 to The Trustees of the University of Pennsylvania to conduct research on cardiac maturation. The project aims to: 1) investigate the role of naturally-occurring variants in human cardiomyocyte genomic estrogen-related receptor (ERR) binding sites and their contribution to heart disease; 2) assess the potential of...
This Project Grant award of $601,563 was provided by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), with a project period from September 1, 2024 to August 31, 2027. The award supports research to investigate the pathogenic roles and molecular mechanisms of the histone lysine demethylases KDM5A and KDM5B in the development and progression of heart failure, with a focus on hereditary cardiomyopathies like Lamin...